I would like to get in touch with someone who have used QIAseq targeted DNA panel. We are struggling with cfDNA libraries and I am wondering if anyone are experiencing the same?
-
-
I do not have experience with QIAseq targeted DNA panel. But can I ask what struggles do you have with cfDNA libraries?
How big is the panel that you are trying to profile?
Thanks!
Cheers,
Sergio -
Hi everyone,
our genetic testing software 'Seamless NGS' offers an easy-to-use workflow for the analysis of Qiagen's QiaSeq panels.
Before mapping the reads, the common sequence and the UMIs are clipped away. After mapping, the UMIs sequences are properly used to correct for PCR clones and the single amplicon primer is clipped away to ensure correct and unbiased variant calling. The workflow was developed, tested and validated together with a trustworthy pathological laboratory at one of the oldest university hospitals in Germany. Having long-lasting experience in that field, together with them, ecSeq was able to get the most out of the QiaSeq panel.
If you are interested in our solution, please check www.seamless-ngs.com and/or write us a short email ([email protected]) to make an appointment for a personal live demo (online).
Last edited by ecSeq Bioinformatics; 05-13-2019, 01:15 AM.ecSeq Bioinformatics is Europe’s leading provider of hands-on bioinformatics workshops and professional data analysis in the field of Next-Generation Sequencing (NGS).Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment